PennyPerformers.com: "Penny Stocks that Perform" pick is: CYTK, EPIC, IPXL, MMDA, UOMO

May 19, 2009 (M2 PRESSWIRE via COMTEX) -- UOMO | Quote | Chart | News | PowerRating -- Pennyperformers.com "Penny Stocks that Perform" picks are: Cytokinetics, Incorporated (NASDAQ: CYTK), Epicor Software Corporation (NASDAQ: EPIC), Impax Laboratories, Inc. (NASDAQ: IPXL), Mega Media Group, Inc. (OTCBB: MMDA), UOMO Media Inc. (OTCBB: UOMO)...and Proudly Introducing Proprietary Push Technology (PPT).

The Newest and Revolutionary Technology for Increasing Investor Visability.

REAL Awareness for REAL Companies.

Click below for a full demonstration.

http://newmediaadvisors.info/newmedia.swf

Sign-up for our FREE Stock Alerts AND NEWSLETTER at www.pennyperformers.com

May 19, 2009 -- Cytokinetics, Incorporated (NASDAQ: CYTK | Quote | Chart | News | PowerRating) announced today that it has entered into definitive agreements with certain of its existing institutional shareholders to sell an aggregate of 7,106,600 units, with each unit consisting of (i) one share of its common stock, $0.001 par value per share ("Common Stock") and (ii) one warrant to purchase 0.50 shares of its Common Stock, in a registered direct offering for gross proceeds of approximately $14.0 million, before deducting placement agents' fees and estimated offering expenses. The investors have agreed to purchase the units for a negotiated price of $1.97 per unit.

The initial per share exercise price of the warrants is $2.75. If by a specified date, Amgen does not obtain an exclusive world-wide (excluding Japan) license to develop and commercialize Cytokinetics' drug candidate, CK-1827452, for the potential treatment for heart failure, pursuant to the rights granted it under the Collaboration and Option Agreement between the parties, then the exercise price of the warrant will be changed to equal the five-day volume average weighted price (VWAP) of Cytokinetics' Common Stock prior to the specified date; however, in such case, the exercise price of the warrants may not exceed $2.75 or be less than $1.50 per share. The warrants are exercisable at any time on or after the closing of this offering and will expire on the date that is thirty months from the date of closing.

The securities described above are being offered directly by Cytokinetics, Incorporated pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission. The company anticipates that the net proceeds from the offering will be used for research and development, including clinical trials for Cytokinetics' drug candidates, working capital and other general corporate purposes. The closing of this offering is expected to occur on or about May 21, 2009, subject to satisfaction of customary closing conditions.

Lazard Capital Markets LLC served as lead placement agent and JMP Securities LLC served as co-placement agent for the offering. Copies of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained from the Securities and Exchange Commission website or from Lazard Capital Markets, LLC.

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration of qualification under the securities laws of any state or jurisdiction.

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' cardiac muscle contractility program is focused on cardiac muscle myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics' lead compound from this program, CK-1827452, a novel small molecule cardiac muscle myosin activator, is in Phase II clinical trials for the treatment of heart failure. Amgen Inc. has obtained an option for an exclusive license to develop and commercialize CK-1827452, subject to Cytokinetics' development and commercialization participation rights. In mid-2009, Cytokinetics plans to initiate a Phase I clinical trial of CK-2017357, a fast skeletal muscle troponin activator, in healthy volunteers in the United States. CK-2017357 is being developed as a potential treatment for diseases and medical conditions associated with aging, muscle wasting, and neuromuscular dysfunction. In January 2009, Cytokinetics announced the selection of a potential drug candidate directed towards smooth muscle contractility; Cytokinetics' smooth muscle myosin inhibitors have arisen from research focused towards potential treatments for diseases and conditions, such as systemic hypertension, pulmonary arterial hypertension or bronchoconstriction.

Cytokinetics' cancer development programs are focused on mitotic kinesins, a family of motor proteins essential to cell division. Cytokinetics is developing two drug candidates that have arisen from this program, ispinesib and SB-743921, each an inhibitor of kinesin spindle protein. In addition, Cytokinetics and GlaxoSmithKline are conducting research and development activities focused on GSK-923295, an inhibitor of centromere-associated protein E (CENP-E).

All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell.

May 19, 2009 -- Epicor Software Corporation (NASDAQ: EPIC), a leading provider of enterprise business software solutions for the midmarket and divisions of Global 1000 companies, today announced that Epicor Chairman, President and CEO George Klaus will be presenting at the Cowen and Company Technology Media and Telecom Conference on Wednesday, May 27, 2009, at 8:00 a.m. EDT at the Palace Hotel in New York City.

A live audio webcast of Epicor's presentation may be accessed at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=EPIC&item_id=2220205 or at Epicor's investor relations website.

About Epicor Software Corporation

Epicor Software is a global leader delivering business software solutions to the manufacturing, distribution, retail, hospitality and services industries. With 20,000 customers in over 150 countries, Epicor provides integrated enterprise resource planning (ERP), customer relationship management (CRM), supply chain management (SCM) and enterprise retail software solutions that enable companies to drive increased efficiency and improve profitability. Founded in 1984, Epicor celebrates 25 years of technology innovation delivering business solutions that provide the scalability and flexibility businesses need to build competitive advantage. Epicor provides a comprehensive range of services with a single point of accountability that promotes rapid return on investment and low total cost of ownership, whether operating business on a local, regional or global scale. The Company's worldwide headquarters are located in Irvine, California with offices and affiliates around the world.

May 19, 2009 -- Impax Laboratories, Inc. (NASDAQ: IPXL | Quote | Chart | News | PowerRating) today confirmed that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's Abbreviated New Drug Application (ANDA) for generic versions of Precose(R) Tablets (acarbose), 25 mg, 50 mg and 100 mg strengths. Precose(R), a Bayer HealthCare Pharmaceuticals product, is used in the management of type two diabetes mellitus.

The Company expects to launch all strengths in the fourth quarter of 2009, through Global Pharmaceuticals, Impax's generic division.

According to Wolters Kluwer Health, U.S. generic and brand sales for Acarbose 25 mg, 50 mg and 100 mg tablets were approximately $32 million for the 12 months ended March 2009.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities.

May 19, 2009 -- Mega Media Group, Inc. (OTCBB: MMDA | Quote | Chart | News | PowerRating) announced that Pulse87 has been retained by Proximo Spirits' Brand, Three Olives Premium Vodka, to market a grassroots promotional program to generate awareness and increase sales on the local New York nightlife circuit. The program includes development of a grassroots initiative and introduction of the Three Olives Pulse Party Girls. The program is designed to develop on-premise awareness of the Three Olives brand selection of premium Vodka Flavors, as well as a strong drive to web component through the Pulse87 website.

Commenting on the announcement, Rick Hernandez, General Sales Manager of Pulse87, stated, "The relationship with Three Olives Brand Premium Vodka began with our First Anniversary Birthday Bash. The decision by Proximo to continue our relationship is a great reflection on our brand and our ability to execute promotionally. We look forward to working with the Proximo team as we execute this program targeting today's active lifestyle and nightlife consumers. This is another example of how our commitment to bringing unique and relevant ideas to our partners continues to set us apart from our competition."

About Three Olives Vodka

The original, ultra-premium vodka from England, Three Olives Vodka is handcrafted in small batches and made from only the finest English wheat. The unmatched method of quadruple distilling and quadruple filtration removes natural impurities, yielding a vodka of exceptional purity and smoothness. Three Olives' vibrant spirit is evident in its colorful array of flavors including Naked, Cherry, Grape, Passion Fruit, Pomegranate, Chocolate, Orange, Berry, Vanilla, Citrus, Raspberry, Watermelon, and Mango, with the recent introductions of Root Beer, Tomato, and Triple Shot Espresso to the Three-O flavor family. At $19.99 and up for a 750 mL bottle, Three Olives award-winning, ultra-premium vodka is now available in 16 flavors, providing connoisseurs with endless mixing possibilities.

May 18, 2009 -- UOMO Media Inc. (OTCBB: UOMO), a multi-channel entertainment company, announced its fully owned subsidiary, The NE Inc, received an East Coast Music Award (ECMA) for their collaboration with director Sean Wainsteim on the video "Weighty Ghost" by Halifax based icons Wintersleep. The video was produced by The NE Inc's President, John Nadalin.

"Our roster of directors are vanguards in music video creativity and we appreciate the recognition by our peers at the ECMAs and the MuchMusic Video Awards," said John Nadalin, President, The NE Inc. "When I was watching the production of the video unravel, I knew Sean, DP Brendan Steacy, and Wintersleep were making some amazing decisions to create a unique visual perspective of the song. This is what our team does - we work with artists to make the song come to life in a unique and visually creative way."

Sean is an award-winning music video director and collaborates with The NE team often. Together Sean and The NE have worked with Skye Sweetnam, The Trews, and Tokyo Police Club among others. Sean has had a long visual collaboration with Wintersleep including directing videos for their songs "Sore", "Danse Macabre", and "Jaws of Life". The video for "Weighty Ghost" was filmed on location in Halifax, NS, where The NE has shot nearly a dozen projects in the last couple years.

About The NE Inc.

Based in Toronto, The NE Inc. is a full service visual media content development company made up of a young collective of like-minded film and television professionals specializing in and developing some of the most pre-eminent visual media, music videos and film projects. The team has secured many accolades including MuchMusic Video awards for music video direction and production. In 2008, The NE Inc. produced almost 40 per cent of Canada's music industry promotions.

About UOMO Media Inc.

UOMO Media Inc. is a multi-channel entertainment company that acquires, produces, and manages intellectual media content and digital assets. UOMO integrates existing and well-established revenue streams in recorded music, publishing and talent management through its five operating divisions: UOMO Digital, UOMO Recorded Music, UOMO Talent Management, UOMO Publishing, and newly launched, AdUOMO.

PricewaterhouseCoopers estimates that by 2011, the global media and entertainment industry will be worth US$ 2 trillion.

About PennyPerformers.com

PennyPerformers.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

Penny Performers email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Penny Performers Report home page at www.PennyPerformers.com and select the "join now" button.

Join us at www.PennyPerformers.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. PennyPerformers.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyPerformers.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. PennyPerformers.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), PennyPerformers.com is owned and operated by PennyPerformers.com. Neither PennyPerformers.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since PennyPerformers.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in PennyPerformers.com statements and opinions and such statements and opinions cannot be considered independent. PennyPerformers.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. PennyPerformers.com services are often paid for using free-trading shares. PennyPerformers.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: www.PennyPerformers.com/disclaimer.htm

CONTACT: PennyPerformers.com e-mail: info@pennyperformers.com WWW: http://www.PennyPerformers.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index